Latest News

Popular (BPOP) has just posted another solid quarter, with Q4 2025 revenue of US$751.8 million and basic EPS of US$3.54, setting the tone as investors look at the new Q1 2026 reporting period. The bank has seen quarterly revenue move from US$689.4 million in Q4 2024 to US$751.8 million in Q4 2025, while basic EPS over that same stretch climbed from US$2.51 to US$3.54, giving you a clear sense of how the income line has scaled alongside the top line. Taken together with an improved net profit...

Katahdin Bankshares (KTHN) has just put another quarter on the board, with Q4 2025 revenue of US$11.9 million and basic EPS of US$0.99 setting the tone after a year in which trailing net income reached US$10.7 million on revenue of US$44.3 million. Over recent periods the company has seen revenue move from US$9.5 million and EPS of roughly US$0.56 in Q4 2024 to US$11.9 million and US$0.99 respectively in Q4 2025. Trailing basic EPS for the last reported twelve months reached about US$3.37...

American Riviera Bancorp (ARBV) opened 2026 with Q1 results that build on a solid finish to last year, with Q4 2025 revenue at about US$14.4 million and basic EPS of roughly US$0.80, while trailing twelve month revenue stood at about US$50.4 million and EPS at roughly US$2.18. Over recent quarters, revenue has moved from about US$10.7 million in Q4 2024 to US$14.4 million in Q4 2025, and basic EPS has shifted from roughly US$0.35 to US$0.80. This sets up a story where higher net income and...

Recently, Surgery Partners reduced its earnings guidance after encountering slower surgical case growth, a less favorable payer mix, and reimbursement pressures across its facilities. An important angle is that the company is still prioritizing higher-acuity procedures and robotics investments, suggesting a focus on reshaping its case mix despite these operational challenges. We’ll now explore how this guidance cut, driven by slower case growth and payer mix headwinds, affects Surgery...

Medpace Holdings (MEDP) has followed up its recent run of strong results with Q4 2025 revenue of US$708.5 million and basic EPS of US$4.78, backing that up with trailing 12 month revenue of about US$2.5 billion and EPS of US$15.64. Over recent quarters the company has seen revenue move from US$533.3 million in Q3 2024 to US$708.5 million in Q4 2025, while quarterly basic EPS has ranged from US$3.11 to US$4.78 across the same stretch. With trailing net profit margins at 17.8% versus 19.2% the...

Mesabi Trust (MSB) has put fresh FY 2026 numbers on the table, with third quarter revenue of US$3.6 million, basic EPS of US$0.21 and net income of US$2.8 million. The trust has seen quarterly revenue move between US$4.7 million and US$6.9 million and EPS range from US$0.28 to US$0.46 over the past year of reported periods, alongside net income between US$3.6 million and US$6.1 million. This sets a clear context for the latest print. With a trailing net margin of 82.8% and earnings quality...

Earlier this week, Manulife Wealth and Asset Management created a global Alternative Investments Specialists distribution team, led by Jeffrey Lindenbaum and David Vincent, to help U.S.-based financial advisors deliver institutional-style alternative credit, real assets, private equity, and private credit solutions to high-net-worth clients. This move highlights Manulife’s push to deepen its presence in higher-fee alternative assets by embedding specialized education and...

Farmers & Merchants Bancorp (FMAO) has put fresh numbers on the board, with Q4 2025 revenue of about US$31.9 million and basic EPS of US$0.70, supported by net income of US$9.7 million as the latest marker ahead of its Q1 2026 reporting period. The business has seen revenue move from US$26.6 million and EPS of US$0.59 in Q4 2024 to US$31.9 million and EPS of US$0.70 in Q4 2025. Trailing 12 month earnings growth of 29.4% and a 27.6% net margin frame a profitability profile that many investors...

Southern Missouri Bancorp (SMBC) opened Q3 2026 with Q2 results that put revenue and earnings in clear focus, reporting total revenue of US$48.0 million and basic EPS of US$1.62 on net income of US$18.1 million. The company has seen revenue move from US$41.7 million with EPS of US$1.10 in Q1 2025 to US$45.1 million and EPS of US$1.40 in Q4 2025, then to US$48.0 million and EPS of US$1.62 in Q2 2026. This latest report can be viewed as part of a steady earnings story that investors can now...

Hansa Biopharma (OM:HNSA) kicked off Q1 2026 with trailing 12 month revenue of SEK 222.3 million and a basic EPS loss of SEK 6.58, while the latest reported quarter in Q4 2025 showed revenue of SEK 76.0 million and a basic EPS loss of SEK 1.67. Over recent quarters, the company has seen quarterly revenue move between SEK 30.8 million and SEK 76.0 million, with basic EPS losses ranging from SEK 0.55 to SEK 2.53. Investors are weighing those headline trends against forecasts that point to...

ONE Gas (OGS) has drawn fresh attention after its recent trading session, with the stock closing at $88.76. For investors, the move brings added focus to how the regulated utility’s fundamentals line up. See our latest analysis for ONE Gas. The latest move to $88.76 comes after a 14.93% 90 day share price return and a 16.97% total shareholder return over the past year, hinting that momentum has been building rather than fading. If this kind of steady utility performance has you thinking about...

Thermo Fisher Scientific (TMO) has just put fresh numbers on the table, with Q4 2025 revenue of US$12.2b and basic EPS of US$5.22 setting the tone against a trailing twelve month EPS of US$17.78 on revenue of US$44.6b, alongside net income of US$6.7b. The company has seen quarterly revenue move from US$10.6b in Q3 2024 to US$12.2b in Q4 2025, while basic EPS over the same period went from US$4.27 to US$5.22. This gives investors a clear read on top line scale and earnings power as they assess...

Kearny Financial (KRNY) has just reported Q3 2026 results with quarterly revenue in the low US$40 million range and basic EPS of about US$0.15, set against a trailing twelve month EPS of US$0.52 that reflects the shift back into profitability. Over recent periods, revenue has moved from US$36.96 million in Q1 2025 to US$42.97 million in Q2 2026, while quarterly EPS has stepped from roughly US$0.10 to just over US$0.15. This gives investors a clearer read on how earnings now sit relative to...

If you are wondering whether Energy Fuels at around $29.93 is priced for perfection or still offers value, the next sections will help you frame that question with numbers rather than guesswork. The stock has seen sharp moves lately, with returns of 4.3% over 7 days, 20.4% over 30 days, 30.5% year to date and 348.7% over 1 year. Recent headlines have focused on Energy Fuels as a key name in uranium and rare earths exposure, with attention on how its projects and resource base position it in...

STMicroelectronics (ENXTPA:STMPA) has agreed to acquire NXP’s MEMS sensor business, expanding its sensor portfolio across key end markets. The company has also entered a new multi year collaboration with Amazon Web Services focused on AI data center infrastructure. These moves come as the shares trade around €42.87 and follow a period of strong stock performance. For investors tracking ENXTPA:STMPA, the latest corporate actions go beyond quarterly headline numbers. The shares trade around...

First Bancorp (FBNC) opened 2026 with Q1 results that put the focus squarely on the income statement, reporting total revenue of US$119.2 million and basic EPS of US$1.13, backed by trailing twelve month revenue of US$393.3 million and EPS of US$2.93. Over recent periods the company has seen quarterly revenue move from US$65.2 million in Q4 2024 to US$104.7 million in Q1 2025, US$108.8 million in Q2, US$86.2 million in Q3 and US$79.2 million in Q4, while EPS shifted from US$0.09 to US$0.88,...

Belite Bio recently initiated a rolling New Drug Application submission to the U.S. FDA for tinlarebant, an investigational oral therapy for Stargardt disease type 1, following completion of a Phase 3 trial and multiple regulatory designations including Breakthrough Therapy and Orphan Drug status. This step positions tinlarebant as a potential first approved treatment for Stargardt disease and highlights Belite Bio’s advancing regulatory and commercialization plans in rare retinal...

flatexDEGIRO (XTRA:FTK) opened Q1 2026 reporting season on the back of a strong finish to 2025, with Q4 total revenue of €147.8 million, basic EPS of €0.37 and trailing 12 month EPS of €1.50 on €557.5 million of revenue, set against year on year earnings growth of 43.9%. Over recent quarters the business has seen revenue progress from €123.9 million in Q4 2024 to €147.8 million in Q4 2025, while trailing 12 month net income moved from €111.5 million to €160.4 million. This gives investors a...

Visa Stock Snapshot After Recent Price Moves Visa (V) has seen mixed share performance recently, with a 1 day return of about a 1% decline, a 2% decline over the past week, and a small positive move over the past month. Over the past 3 months, the stock shows roughly a 5% decline and the year to date return is about an 11% decline, while the 1 year total return is about a 7% decline for investors holding through this period. See our latest analysis for Visa. Visa’s recent share price...

In April 2026, Teradata Corporation announced that its enterprise-grade Analyst Agent became available on Microsoft Marketplace, giving Azure customers a no-code, conversational analytics tool that orchestrates complex SQL queries and visualizations within their existing Teradata and Azure environments. A distinctive feature of this launch is Teradata’s Agent Telemetry, which makes the AI agent’s reasoning observable and auditable, allowing enterprises to configure custom quality signals and...

Roku (ROKU) is back in focus after a strong six month run, outpacing the S&P 500. The stock has drawn renewed attention alongside solid quarterly results, higher streaming hours, improving free cash flow margin, and growing interest ahead of upcoming earnings. See our latest analysis for Roku. The recent 30 day share price return of 20.26% and a 1 year total shareholder return of 77.82% suggest momentum has been building, although the 5 year total shareholder return of a 67.77% loss shows...

With inflation pressures, higher energy costs and uncertain rate paths shaping markets, many investors are looking for leaders whose incentives are tightly aligned with shareholders. Founder led companies often fit that brief, with high capital efficiency and real skin in the game that can help keep spending disciplined and focus sharp when input costs, funding and demand all feel less predictable. This article looks at three stocks from our Top Founder-Led Companies screener, giving you a...

Dover (DOV) kicked off Q1 2026 against a backdrop of recent quarterly revenue between US$1.87 billion and US$2.10 billion and basic EPS ranging from US$1.74 to US$2.21 through 2025, with trailing 12 month revenue at about US$8.09 billion and EPS at US$8.01. Over that same trailing period, revenue has stayed in a tight band around US$7.72 billion to US$8.09 billion, while EPS moved between US$7.55 and US$8.01. This provides a clear sense of how top line and per share earnings have been...

Mercedes-Benz Group (XTRA:MBG) is back in focus after a cluster of long term partnerships across electric vehicles, batteries and in car artificial intelligence raised fresh questions about how its technology roadmap might influence the stock. See our latest analysis for Mercedes-Benz Group. Despite the recent partnerships around EV batteries, charging and in car AI, momentum in the shares has softened, with a 90 day share price return of 13.24% decline and a year to date share price return...